Diagnosis and management of patients with bipolar disorder in primary care by Berk, Michael et al.
Deakin Research Online 
 
This is the published version:  
 
 
Berk, Michael, Dodd, Seetal, Berk, Lesley and Opie, Jane 2005, Diagnosis and management 
of patients with bipolar disorder in primary care, British journal of general practice, vol. 55, 
no. 518, pp. 662-664.  
 




Reproduced with the kind permission of the copyright owner. 
 
 
Copyright : 2005, Royal College of General Practitioners 
Bipolar disorder has previously been
reported as having a prevalence of
approximately 1%, although there is new
data that prevalence rates may actually be
as high as 5%.1 It is therefore likely that
GPs will frequently encounter bipolar
patients in their practice. New research
suggests that up to 30% of patients
presenting with depression in primary care
may have a primary diagnosis of bipolar
disorder.2 The disorder is characterised by
mood fluctuations that include mania,
hypomania, depression, and mixed
episodes. It is chronic and highly recurrent,
and associated with significant distress
and disability.3 The World Health
Organisation ranks bipolar disorder as the
world’s sixth leading cause of disability-
adjusted life years among people aged
15–44 years. As many as 25–50% of
patients with bipolar disorder attempt
suicide during their lifetime.4
Bipolar disorder is distinguished from
unipolar depression by the presence of a
current or past episode of mania or
hypomania.5 Most bipolar patients
present with depressive symptoms rather
than mania. Active enquiry regarding past
mania or hypomania is essential to
establish the true diagnosis. The
diagnosis may also be blurred by
common comorbidities, in particular
substance abuse, personality and anxiety
disorders. As a consequence, bipolarity
is characteristically hard to diagnose in
primary care. In one study, only 52% of
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sufferers receive a diagnosis by the first
or second professional they consult. A
diagnosis of bipolar disorder was made in
less than 1 year from their first
professional contact for only 29% of
sufferers, but more than 10 years for 34%
of sufferers.6
The differentiation into unipolar and
bipolar disorder would be semantic if it
did not have treatment or prognostic
implications. There is clear evidence that
the distinction is a therapeutic
imperative. Treatments for the two
disorders are substantially different and
there is increasing evidence that treating
patients with bipolar disorder with
unipolar therapy algorithms may lead to
unfavourable outcomes. This imperative
is underlined by studies that suggest that
bipolar disorder is among the most
treatment responsive and cost-effective
disorders to treat among the major
disorders in psychiatry.7
There are several signs and symptoms
that may alert the GP to the possibility
that a patient presenting with depression
may suffer from bipolar illness. These
include a family history of bipolar illness,
particularly in a first degree relative.8
Precipitation of mania or hypomania with
antidepressant treatment will confirm a
diagnosis of bipolar disorder, although
more commonly bipolar disorder
sufferers simply fail to respond to
antidepressant treatment. Further, where
there is failure to respond to three or
more antidepressant treatment trials,
bipolar disorder should be suspected.8
The presence of atypical depressive
features particularly hypersomnia, should
alert clinicians to consider possible
bipolarity, as should abrupt onset and
offset of episodes and a seasonal
pattern. Bipolar disorder has an earlier
age of onset than unipolar depression, so
it should also be considered in cases
where depression appears before the age
of 25 years.8
Mood stabilisers are the foundation of
therapy for bipolar disorder, and current
guidelines recommend use of a mood
stabiliser in all phases of treatment.9
Lithium is the most extensively studied
mood stabiliser and has been used for
both acute,10–12 and prophylactic12,13
treatment of bipolar disorder. Lithium has
also been found to robustly reduce the
risk of suicide.9,14 Valproate has clear
efficacy in the treatment of mania,10,11 but
there is less evidence of its efficacy in
bipolar disorder maintenance.15
Carbamazepine has demonstrated acute
antimanic effects,16 and efficacy as a
long-term maintenance agent for
sufferers of bipolar disorder.13,17
Lamotrigine has been found to be
efficacious in the acute management of
bipolar depression18 and long-term
management of bipolar disorder,
especially in delaying depressive
recurrence.19 This antidepressant
dominant profile contrasts with the
predominantly antimanic activity seen
with other mood stabilisers. Lastly,
atypical antipsychotics like clozapine,
risperidone, ziprasidone and olanzapine
are clearly efficacious in acutely manic
patients. There is early evidence of
efficacy of quetiapine and olanzapine in
bipolar depression and evidence for the
role of olanzapine in maintenance. 
Analysis of marketing data suggests
that antidepressants may be more
commonly prescribed for use in bipolar
disorder than mood stabilisers in some
areas.20 However, increasing data points
to the risks of inducing mania, rapid
cycling or mixed states.21 Both rapid
cycling, an increase in the number of
episodes of illness over time, and mixed
states, the occurrence of both manic and
depressive symptoms at the same time,
are particularly malignant and treatment
refractory variants of the illness. While
studies have suggested a role for
antidepressants in the acute treatment of
the depressive phase of bipolar
disorder,22 there is scant evidence for
long-term use.23 Indeed, switching to
mania or hypomania may be a cumulative
risk in the continuation phase of
antidepressant therapy. The field is
hampered by the lack of a coherent
dataset in this regard.24
There is robust evidence suggesting a
link between the number of previous
episodes experienced by the individual
and the risk of future episodes,25 so
relapse prevention strategies are crucial
to reduce the morbidity associated with
the disorder. The potential of medication
to reduce relapse is not always achieved
in clinical settings.26 This may be due at
least in part to the problem of non-
adherence to prescribed long-term
medical treatment in bipolar disorder.
Psychosocial interventions that improve
medication adherence as well as
enhancing overall patient care may serve
as a useful adjunct to management in the
primary care setting. Various
psychosocial interventions including
cognitive behavioural therapy,27 family
therapy28 or Interpersonal and Social
Rhythm Therapy29 involve a
psychoeducation component and focus
on relapse prevention through increased
awareness of illness patterns and
prodromes and coping skills to prevent
full-blown relapse. These interventions
have variously shown improvements in
time to relapse, admission rates, length
of affective episodes, affective
symptomatology and social functioning.
In conclusion, accurate differentiation
between unipolar and bipolar disorder is
critical. The clinical risk to bipolar
patients if they are treated as if they had
unipolar depression, is the likelihood that
primary treatment will be with
antidepressants, rather than mood
stabilisers, with the risk of iatrogenic
aggravation of the illness. Primary care
physicians are often the first clinicians to
screen for bipolar disorder and manage
its initial manifestations. In many models
of care they are also primarily responsible
for the long-term management of bipolar
patients after specialist stabilisation.
They play a pivotal role in detecting,
managing and, where necessary, the
appropriate referral of patients with
bipolar disorder. This role is essential in
the management of this highly prevalent
and disabling yet treatable condition. 
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